U.S. markets open in 6 hours 23 minutes

Agenus Inc. (AGEN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.3950-0.2650 (-7.24%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close3.6600
Open3.6300
Bid0.0000 x 1100
Ask0.0000 x 3200
Day's Range3.3900 - 3.6850
52 Week Range1.8200 - 5.9500
Volume3,552,127
Avg. Volume2,943,459
Market Cap645.556M
Beta (5Y Monthly)1.67
PE Ratio (TTM)N/A
EPS (TTM)-1.0930
Earnings DateMar 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2020 Financial Report
    GlobeNewswire

    Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2020 Financial Report

    Conference Call on Monday, March 15, 2021 at 8:30 a.m. ETLEXINGTON, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it will release its fourth quarter and full year 2020 financial results before the market opens on Monday, March 15, 2021. Agenus executives will host a conference call and webcast at 8:30 a.m. ET the same day to discuss the results and to provide a corporate update. Conference CallDial-in numbers: (833) 614-1394 (US) or (914) 987-7115 (International); Conference ID: 2339028. WebcastA live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.agenusbio.com/events-and-presentations and via https://edge.media-server.com/mmc/p/3f7iind8. About AgenusAgenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter. ContactAgenus Investor RelationsJan Medina, CFAAgenus781-674-4490Jan.Medina@agenusbio.com Agenus Media RelationsKimberly HaKKH Advisors917-291-5744kimberly.ha@kkhadvisors.com

  • Andy Hurley Named Agenus Chief Commercial Officer
    GlobeNewswire

    Andy Hurley Named Agenus Chief Commercial Officer

    LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the appointment of Andy Hurley as its Chief Commercial Officer. “We welcome Andy Hurley as we transition into a commercial stage company with a robust research and clinical pipeline,” said Garo Armen, PhD, Chairman and CEO of Agenus. “Andy’s experience and passion in successfully commercializing biopharmaceutical agents and his excitement about our portfolio made him a natural fit to join our team.” "I am excited to join Agenus, one of the true pioneers in immuno-oncology, to lead the efforts for its first potential commercial product launch and to help determine the optimal commercial path for Agenus’ vast and differentiated pipeline,” said Andy Hurley, Chief Commercial Officer at Agenus. “I am excited about the potential of balstilimab alone and in combination with Agenus’ other novel candidates, like AGEN1181, to bring potentially life-altering therapies to patients.” Andy brings to Agenus three decades of international experience as a strategic commercial leader at large and small biopharmaceutical companies. He joins Agenus from his most recent role as the Senior Vice President at Syneos Health. Before Syneos Health, he was Chief Commercial Officer at Ocular Therapeutix where he was hired to pivot the organization from an R&D company to a fully integrated commercial company. Andy also held executive leadership roles at Sunovion, Dyax, and Forest Pharmaceuticals. He holds a Bachelor of Science in Consumer Studies from the University of Vermont. About AgenusAgenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter. Forward-Looking StatementsThis press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding commercialization and the anticipated commercial launch of Agenus’ candidates, as well as their therapeutic potential. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Contact:Agenus Inc. Caroline Bafundo 212-994-8209Caroline.Bafundo@agenusbio.com

  • Agenus Announces Agenus Insights - Virtual R&D Miniseries
    GlobeNewswire

    Agenus Announces Agenus Insights - Virtual R&D Miniseries

    Season 1 Episode 1 (S1E1) on “Optimally Targeting TIGIT” LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it will host its inaugural Agenus Insights on “Optimally Targeting TIGIT” on Thursday, February 11, 2021 at 1:00 p.m. ET. This R&D miniseries, a brief yet concise summary of key insights into the most impactful areas of research in immuno-oncology and Agenus’ contributions to them, will include a 15-minute presentation and a 15-minute Q&A session. S1E1, “Optimally Targeting TIGIT,” will be hosted by Dr. Steven O’Day, Chief Medical Officer, and Dr. Dhan Chand, Scientific Director, Head of Drug Discovery. The webinar will begin with a fast-paced discussion by Dr. Steven O’Day and Dr. Dhan Chan highlighting the clinical validation of TIGIT as an anti-cancer target and the rationale for Agenus’ Fc-enhanced design. The remainder of the webinar will be made available for a Q&A session. Registration for the webinar can be done in advance at https://agenusbio.zoom.us/webinar/register/WN_tOrL5VCkRoSh7lFKqOCKAA. A replay will be available after the webinar on the Events & Presentations page of the Agenus website at https://investor.agenusbio.com/events-and-presentations. About AgenusAgenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter. Forward-Looking StatementsThis press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding TIGIT. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Contact:Agenus Inc. Caroline Bafundo 212-994-8209Caroline.Bafundo@agenusbio.com